5 Best Healthcare REIT Stocks for 2026 and How to Invest - The Motley Fool

Open this photo in gallery:Asset managers Mill Pond Capital LLC, which owns 2.2 million H&R units, said the offer favours Mr. Hofstedter and his family at the expense of other unitholders. Fred Lum/The Globe and MailA founder-backed takeover bid for H&R Real Estate Investment Trust is facing growing opposition ahead of recommendations from proxy advisory services that could kill the $3.4-billion acquisition. Last week, several institutional investors came out against a units-and-cash offer for Toronto-based H&R from a consortium led by GO Residential Real Estate Investment Trust and including H&R’s founder and chief executive officer, Tom Hofstedter.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.